A recombinant vaccinia virus based ELISPOT assay detects high frequencies of pol-specific CD8 T cells in HIV-1-positive individuals

AIDS

Volumn 13, Issue 7, 1999, Pages 767-777

  Larsson, Marie ^d   Jin, Xia ^a   Ramratnam, Bharat ^a   Ogg, Graham S ^c   Engelmayer, Jose ^d   Demoitie, Marie Ange ^a   McMichael, Andrew J ^c   Cox, William I ^b   Steinman, Ralph M ^d   Nixon, Douglas ^a   Bhardwaj, Nina ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c Virogenetics Corporation   (United States)

^d NONE

Author keywords

Canarypox; Cytotoxic T lymphocytes; ELISPOT assay; HIV 1; Vaccinia

Indexed keywords

ANTIRETROVIRUS AGENT; CD8 ANTIGEN; GAG PROTEIN; GAMMA INTERFERON; HLA A ANTIGEN; HORSERADISH PEROXIDASE; MONOCLONAL ANTIBODY; NEF PROTEIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DILUTION; EFFECTOR CELL; ENVELOPE GENE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MEMORY CELL; MONONUCLEAR CELL; PRIORITY JOURNAL; STRUCTURAL GENE; T LYMPHOCYTE; VACCINIA VIRUS; VIRUS RECOMBINANT;

ADULT; ANTI-HIV AGENTS; CD8-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENES, POL; GENETIC VECTORS; HIV ANTIGENS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; VACCINIA VIRUS;

EID: 3843084310     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199905070-00005     Document Type: Article

References (30)

1. 1. McMichael AJ, Phillips RE: Escape of human immunodeficiency virus from immune control. Ann Rev Immunol 1997, 15:271-296.
2. 2. Jassoy C, Walker BD: T lymphocytes and their cytokines in human immunodeficiency virus (HIV) infection: Implications for associated neoplasias. Crit Rev 1998, 6:275-289.
3. 3. Steinman RM, Germain RN: Antigen presentation and related immunological aspects of HIV-1 vaccines. AIDS 1998, 12:597-5112.
4. 4. Borrow P: Mechanisms of viral clearance and persistence. J Viral Hepatitis 1997, 4:16-24.
5. 5. Goulder P, Price D, Nowak M, Rowland-Jones S, Phillips R, McMichael A: Co-evolution of human immuno-deficiency virus and cytotoxic T-lymphocyte responses. Immunol Rev 1997, 159:17-29.
6. 6. Sipsas N, Kalams SA, Trocha A, He S, Blattner WA, Walker BD: Identification of type-specific cytotoxic T lymphocyte responses to homologous viral proteins in laboratory workers accidentally infected with HIV-1. J Clin Invest 1997, 99:752-762.
7. 7. Rowland-Jones S, Sutton J, Ariyoshi K, et al.: HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nature Med 1995, 1:59-64.
8. 8. Ogg GS, Jin X, Bonhoeffer S, et al.: Quantitation of HIV-1 specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998, 279:2103-2106.
9. 9. Callan MFC, Ian L, Annels N, et al.: Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo. J Exp Med 1998, 187:1395-1402.
10. 10. Kuroda M J, Schmitz JE, Barouch DH. et al.: Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex. J Exp Med 1998, 187:1373-1381.
11. 11. Gallimore A, Glithero A, Godkin A, et al.: Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J Exp Med 1998, 187:1383-1393.
12. 12. Busch DH, Pilip I, Pamer EG: Evolution of a complex T cell receptor repertoire during primary and recall bacterial infection. J Exp Med 1998, 188:61-70.
13. + memory T cells. J Exp Med 1997, 186:859-865.
14. 14. Lalvani A, Brookes R, Wilkinson RJ, et al.: Human cytolytic and interferon γ-secreting CD8+ T lymphocytes specific for Mycobacterium tuberculosis. Proc Natl Acad Sci, USA 1998, 95:270-275.
15. 15. McCutcheon M, Wehner N, Wensky A, et al.: A sensitive ELISPOT assay to detect low-frequency human T lymphocytes. J Immunol Methods 1997, 210:149-166.
16. 16. Schmittel A, Keilholz U, Scheibenbogen C: Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood. J Immunol Methods 1997, 210:167-174.
17. 17. Herr W, Protzer U, Lohse AW, Gerken G, zum Buschenfelde K-HM, Wolfel T: Quantification of CD8+ T lymphocytes responsive to human immunodeficiency virus (HIV) peptide antigens in HIV-infected patients and seronegative persons at high risk for recent HIV exposure. J Infect Dis 1998, 178:260-265.
18. 18. Cadoz M, Strady A, Meignier B, et al.: Immunisation with canarypox virus expressing rabies glycoprotein. Lancet 1992, 339:1429-1432.
19. 19. Lartaglia J, Cox WI, Taylor J, et al.: Highly attenuated poxvirus vectors. AIDS Res Hum Retroviruses 1992, 8:1445-1447.
20. 20. Cox WI, Lartaglia J, Paoletti E: Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein. Virology 1993, 195:845-850.
21. 21. Bhardwaj N, Bender A, Gonzalez N, Bui LK, Garrett MC, Steinman RM: Influenza virus-infected dendritic cells stimulate strong proliferate and cytolytic responses from human CD8+ T cells. J Clin Invest 1994, 94:797-807.
22. 22. Musey L, Hughes J, Schacker I, Shea T, Corey I, McElrath J: Cytotoxic T cell responses viral load, and disease progression in early human immunodeficiency virus type 1 infection. New Engl J Med 1997, 137:1267-1274.
23. 23. Koup RA, Safrit JT, Yunzhen C et al.: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994, 68:4650-4655.
24. 24. Carmichael A, Jin X, Sissons P, Borysiewicz L: Quantitative analysis of the human HIV-1 specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: Differential CTL response to HIV-1 and Epstein-Barr virus in late disease. J Exp Med 1993, 177:249-256.
25. 25. Bennink JR, Yewdell JW: Recombinant vaccinia viruses as vectors for studying T lymphocyte specificity and function. Curr Topics Microbiol Immunol 1990, 163:153-184.
26. 26. Tartaglia J, Jarrett O, Neil JC, Desmettre P, Paoletti E: Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL. J Virol 1993, 67:2370-2375.
27. 27. Coulder PJR, Sewell AK, Lalloo DG, et al.: Patterns of immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA)-identical siblings with HLA-A *0201 art influenced by epitope mutation. J Exp Med 1997, 185:1423-1433.
28. 28. Brander C, Hartman KE, Trocha A, et al.: Lack of strong immune selection pressure by the immunodominant, HLA-A *0201-restricted cytotoxic T lymphocyte response in chronic human immunodeficiency virus-1 infection. J Clin Invest 1998, 101:2559-2566.
29. 29. Jin, X, Roberts CGP, Nixon DF et al.: Longitudinal and cross-sectional analysis of cytotoxic T lymphocyte (CTL) responses and their relationship to vertical human immunodeficiency virus (HIV) transmission. J Infect Dis 1998, (in press).
30. 30. Korber B, Walker B, Brander C, et al.: HIV Molecular Immunology Database. Los Alamos, New Mexico: Los Alamos National Laboratory. Theoretical Biology and & Biophysics; 1996.